-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

651.P1.51 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational: Poster I

Program: Oral and Poster Abstracts
Type: Poster
Saturday, December 11, 2021: 5:30 PM-7:30 PM
Hall B5, Level 1, Building B (Georgia World Congress Center)

Cathelijne Fokkema, MD1*, Madelon M.E. de Jong, MD1*, Sabrin Tahri, MD1*, Zoltan Kellermayer, MD, PhD1*, Chelsea den Hollander, BSc1*, Michael Vermeulen, BSc1*, Natalie Papazian1*, Mark van Duin, PhD1*, Michiel J.W. Wevers, MSc1*, Mathijs A. Sanders, PhD, MSc1*, Vincent H.J. van der Velden, PhD2*, Pieter Sonneveld, MD, PhD1, Annemiek Broyl1* and Tom Cupedo, PhD1*

1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
2Department of Immunology, Laboratory Medical Immunology, Erasmus University Medical Center, Rotterdam, Netherlands

Selina J Chavda, MBBS, BSc, MRCP, FRCPATH1*, Daria Galas-Filipowicz2*, Evelyn Fitzsimons, BSc1*, Anna Mikolajczak, BSc, MSc1*, Sharon Tooze, PhD, Professor3*, Holger W Auner, MD, PhD4, Katja Simon, PhD5*, Asim Khwaja, MD, FRCP, FRCPATH1* and Kwee Yong, MD, PhD1*

1Cancer Institute, Department of Haematology, University College London, London, United Kingdom
2Cancer Institute, Department of Haematology, UCL, London, United Kingdom
3Francis Crick Institute, London, United Kingdom
4Imperial College London, London, United Kingdom
5University of Oxford, Oxford, United Kingdom

Niels Van Nieuwenhuijzen, MD1,2*, Marta Cuenca, PhD1*, Leonie Abbink2*, Eline Lammers, MD2*, Margot Jak, MD, PhD2*, Victor Peperzak, PhD1* and Monique C. Minnema, MD2

1Center for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
2Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands

Mariah Farrell, MS1,2,3*, Heather Fairfield, MS1,2,3*, Anastasia D'Amico, BS1*, Connor S Murphy, BS1,4*, Carolyne Falank, PhD1*, Catherine R. Marinac, PhD5, Sklavenitis-Pistofidis Romanos, MD6*, Amanda Cao7*, Julie Dragon, PhD8* and Michaela R Reagan, PhD2,3,9

1Maine Medical Center Research Institute, Scarborough, ME
2Tufts University School of Medicine, Boston, MA
3University of Maine, Orono, ME
4Graduate School of Biomedical Science and Engineering, University of Maine, Orono, ME
5Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
6Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
7Dana-Farber Cancer Institute, Boston, MA
8University of Vermont, Burlington, VT
9Maine Medical Center Research Institute, South Portland, ME

Roisin M McAvera*, Jonathan J Morgan, BSc, MRes*, Ken I Mills and Lisa J Crawford, BSc, PhD*

Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom

Jonas Schwestermann, MSc1*, Andrej Besse, PhD1*, Lenka Besse, PhD1* and Christoph Driessen, MD2

1Laboratory of Experimental Oncology, Clinics for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
2Laboratory of Experimental Oncology, Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

Shiqiao Ye, PhD, BSc, MSc1*, Yu Chen1*, Bo Hu, PhD1*, Huayu Huang, MSc1*, Yuxiao Sun, MD. PhD1*, James P Stewart, PhD1*, Sarah K Johnson, PhD1*, Bart Barlogie, MD.PhD2*, Maurizio Zangari, MD, FACP1, Guido Tricot, MD. PhD1*, Faith E Davies, MD3, Gareth J Morgan, MD, PhD3*, Brian A Walker, PhD4, Fenghuang Zhan, MD. PhD1, Frits van Rhee, MD PhD2, John D Shaughnessy Jr., PhD1* and Ya-Wei Qiang, MD, PhD1

1Myeloma Center, Division of Hematology/Oncology, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR
2Myeloma Center, Winthrop P. Rockefeller Institute, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR
3Perlmutter Cancer Center, NYU Langone Health, New York, NY
4Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, Indianapolis, IN

Natthakan Thongon, PhD1, Andrea Santoni, PhD1*, Jintan Liu, PhD2*, Natalia Baran, PhD, MD1, Feiyang Ma, PhD3*, Christopher Jackson, BS1*, Pamela Lockyer, MS1*, Irene Ganan-Gomez, PhD1, Vera Adema, PhD1*, Ashley Rose, MD4, Matteo Marchesini, PhD1,5*, Yun Qing, PhD6*, Min Jin Ha, PhD6*, Caleb Class, PhD6*, Matteo Pellegrini, PhD3*, Lin Tan7*, Philip Lorenzi, PhD8, Marina Konopleva, MD, PhD1 and Simona Colla, PhD1*

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
3Molecular Biology Institute, Molecular Cell and Developmental Biology, University of California, Los Angeles, Los Angeles, CA
4Department of Leukemia, The University of Texas MD Anderson Cancer Center, Tampa, FL
5Department of Medicine and Surgery, University of Parma, Parma, Italy
6Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
7Department of Bioinformatics and Computational Biology and The Proteomics and Metabolomics Core Facility, The University of Texas MD Anderson Cancer Center, Houston, TX
8Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX

Inge Oudaert, MSc1*, Hatice Satilmis1*, Philip Vlummens, MD1,2*, Anke Maes, PhD1*, Elke De Bruyne, PhD1*, Karin Vanderkerken, PhD1, Sarah-Maria Fendt, PhD3,4*, Kim De Veirman, PhD1* and Eline Menu, PhD1*

1Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium
2UZ Gent, Gent, Belgium
3Laboratory of Cellular Metabolism and Metabolic Regulation, VIB, Leuven, Belgium
4Laboratory of Cellular Metabolism and Metabolic Regulation, UZ Leuven, Leuven, Belgium

Chao Zhang, PhD1,2*, Xiaoxuan Xu, MD1*, Timothy Trotter, PhD1*, Amjad Javed, PhD3,4*, Joanne E. Murphy-Ullrich, PhD1*, Juan Li, PhD2 and Yang Yang, MD1,4

1Department of Pathology, University of Alabama at Birmingham, Birmingham, AL
2First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China
3Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Alabama at Birmingham, Birmingham, AL
4Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL

Maria Moscvin1*, Tianzeng Chen, MS2*, Peter G. Czarnecki, MD3*, Annamaria Gulla, MD4, Kenneth C. Anderson, MD5 and Giada Bianchi, MD2,6

1Brigham and Women's Hospital, Boston, MA
2Amyloidosis Program, Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Boston, MA
3Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA
4Medical Oncology, Dana Farber Cancer Institute, Boston, MA
5Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
6Harvard Medical School, Boston, MA

Andrej Besse, PhD1*, Lenka Besse, PhD1*, Lorina Büchler1*, Sara C. Stolze2*, Amin Sobh, PhD3, Marianne Kraus1*, Hirofumi Nakagami2* and Christoph Driessen, MD4

1Laboratory of Experimental Oncology, Clinics for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
2Protein Mass Spectrometry Group, Max Planck Institute for Plant Breeding Research, Cologne, Germany
3Cancer and Genetics Research Complex, University of Florida, Gainesville, FL
4Laboratory of Experimental Oncology, Clinic for Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland

Sabrin Tahri, MD1*, Zoltan Kellermayer, MD, PhD1*, Madelon M.E. de Jong, MD1*, Natalie Papazian1*, Cathelijne Fokkema, MD1*, Chelsea den Hollander, BSc1*, Pieter van de Woestijne, MD PhD2*, Mark van Duin, PhD1*, Annemiek Broijl, MD, PhD1*, Pieter Sonneveld, MD, PhD1 and Tom Cupedo, PhD1*

1Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
2Department of Thoracic Surgery, Erasmus MC, Rotterdam, Netherlands

Sebastian Köhrer1,2*, Tobias Dittrich, MD1,2,3,4*, Martin Schorb, PhD5*, Niels Weinhold, PhD3*, Isabella Haberbosch, MD2,3*, Mandy Börmel, PhD5*, Gabor Pajor, PhD2*, Hartmut Goldschmidt, MD3,6, Carsten Müller-Tidow, MD3,6*, Marc-Steffen Raab, MD2,3*, Alexander Brobeil, MD7*, Peter Dreger, MD3, Ute Hegenbart, MD4,8*, Stefan Schönland3,4*, Yannick Schwab, PhD1,5* and Alwin Krämer, MD2,3*

1Cell Biology and Biophysics Unit, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
2Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
3Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
4Amyloidosis Center, University of Heidelberg, Heidelberg, Germany
5Electron Microscopy Core Facility, European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
6National Center for Tumor Diseases (NCT), University of Heidelberg, Heidelberg, Germany
7Institute of Pathology, University of Heidelberg, Heidelberg, Germany
8Internal Medicine V - Hematology, Oncology & Rheumatology, University Hospital Heidelberg, Heidelberg, Baden-W., Germany

Yawara Kawano, MD, PhD1, Saki Kushima2*, Hiroyuki Hata, MD, PhD,3 and Masao Matsuoka, MD, PhD4

1Department of Hematology, Kumamoto University Hospital, Kumamoto, Japan
2Graduate School of Health Sciences, Kumamoto University, Kumamoto, Japan
3Division of Informative Clinical Sciences, Faculty of Medical Sciences, Kumamoto University School of Health Science, Kumamoto, Japan
4Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan

Danielle C Croucher, MSc1,2*, Laura M Richards1,2*, Zhihua Li, MSc1*, Ellen nong Wei, Msc1*, Xian Fang Huang3*, Daniel Waller, PhD3*, Marta Chesi, PhD4, P. Leif Bergsagel, MD5, Michael Sebag, MD, PhD6, Trevor J. Pugh, PhD1,2,7* and Suzanne Trudel, MD1,2

1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
3McGill University Health Centre, Montreal, QC, Canada
4Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ
5Division of Hematology, Mayo Clinic, Scottsdale, AZ
6Division of Hematology, McGill University Health Centre, Montreal, QC, Canada
7Ontario Institute for Cancer Research, Toronto, Canada

Laure Dutrieux1*, Yea-Lih Lin, PhD2*, Malik Lutzmann, PhD2*, Guilhem Requirand3*, Nicolas Robert3*, Laure Vincent, MD4*, Guillaume Cartron, MD, PhD5,6,7,8*, Charles Herbaux, MD9, Raphael Rodriguez10*, Michel Cogne11*, Philippe Pasero, PhD2* and Jerome Moreaux, PhD2,3,12,13

1Institute of human genetics, UMR CNRS-UM 9002, Montpellier, France
2Institute of Human Genetics, UMR 9002 CNRS-UM, Montpellier, France
3Laboratory for Monitoring Innovative Therapies, Department of Biological Hematology, CHU Montpellier, Montpellier, France
4CHU de Montpellier / Département d'hématologie clinique, Hôpital Saint-Eloi, Montpellier, France
5Département d'Hématologie clinique, CHU de Montpellier, Montpellier, France
6Montpellier University, UMR CNRS 5235, Montpellier, France
7Hematology Department, Montpellier University Hospital, Montpellier, France
8Department of Clinical Hematology and Unite Mixte de Recherche (UMR), Centre National de la Recherche Scientifique (CNRS), CHRU, Montpellier, France
9Hematology Department, Montpellier University Hospital, Montpellier, France, Montpellier, France
10Institut Curie, Paris, France
11Centre National De La Recherche Scientifique UMR CNRS 7276/INSERM U1262, Univers, LIMOGES, FRA
12UFR Médecine, Université Montpellier, Montpellier, France
13Institut Universitaire de France, Paris, France

Melissa Vrohlings1*, Jan Müller, MD2*, Stephanie Jungmichel1*, David Senn1*, Anna Bianca Howald1*, Thomas Schleier1*, Fabian Scheifele1*, Severin Wendelspiess1*, Philipp Richle1*, Hannes Merten1*, Daniel Lenherr-Frey1*, Christian Leisner1*, Markus G Manz, MD2 and Leonardo J. Borras1*

1CDR-Life Inc, Schlieren, Switzerland
2Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland

Ling-Ling Shu, PhD1, Shuzhao Chen2*, Jinyuan Li1*, Weida Wang, MD, PhD1*, Yang Liu3*, Yang Li4*, Han-Ying Huang5*, Xiaoping Wu6* and Yang Liang, MD, PhD7

1State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
2State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, AL, China
3Zhujiang Hospital, Southern Medical University, Guangzhou, CHN
4Sun Yat-Sen University Cancer Center, Guangzhou, CHN
5Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology In South, Guangzhou, China
6State Key Laboratory of Pharmaceutical Biotechnology, The University of Hong Kon, Hong Kong, CHN
7State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine; Department of Hematologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Sun Yat-sen University Cancer Center, Guangzhou, China

David M Foureau, PhD1, Manisha Bhutani, MD2, Fei Guo, PhD2*, Kateryna Fesenkova2*, Shebli Atrash, MD3, Reed Friend, MD3, Barry Paul, MD, MS4, Myra M Robinson, MSPH5*, James T Symanowski, PhD6*, Lawrence J Druhan, PhD7, Mauricio Pineda-Roman, MD3, Peter M. Voorhees, MD3 and Saad Z. Usmani, MD MBA FACP3

1Immune Monitoring Core Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, NC
2Levine Cancer Institute, Atrium Health, Charlotte, NC
3Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
4Plasma Cell Disorders Section, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
5Levine Cancer Institute, Charlotte, NC
6Department of Cancer Biostatistics, Levine Cancer Institute, Atrium Health, Charlotte, NC
7Hematology Oncology Translational Research Laboratory, Levine Cancer Institute, Atrium Health, Charlotte, NC

Amin Sobh, PhD1,2, Charlotte L Kaestner, BS1, Jianping Li, MD1, Alberto Riva, PhD2*, Richard Lynn Bennett, PhD1 and Jonathan D. Licht, MD1

1Department of Medicine, University of Florida, Gainesville, FL
2Cancer and Genetics Research Complex, University of Florida, Gainesville, FL

Pooja Shah, MSc1*, Thorsten Stuehmer, PhD2*, Daniela Bruennert, PhD3*, Umair Munawar, PhD1*, Ellen Leich, PhD4*, Sabrina Kraus, MD1*, Michael Hudecek, MD1*, Manik Chatterjee, MD2*, Andreas Schlosser, PhD5*, Ralf C Bargou, MD2*, Hermann Einsele1, Friederike Berberich-Siebelt, PhD4* and Torsten Steinbrunn1*

1Department of Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany
2Comprehensive Cancer Center Mainfranken, University Hospital of Wuerzburg, Wuerzburg, Germany
3Department of Obstetrics and Gynecology, University Hospital of Wuerzburg, Wuerzburg, Germany
4Institute of Pathology, University of Wuerzburg, Wuerzburg, Germany
5Rudolf Virchow Center for Experimental Biomedicine, University of Wuerzburg, Wuerzburg, Germany

Munevver Cinar, MD1*, Badri Vardarajan, PhD2*, Neil Anthony, PhD3*, Bassel El-Rayes, MD3*, Ganji Nagaraju4*, Lourdes Martinez-Medina, PhD5*, Jean-Michel Gries, PharmD6* and Leon Bernal-Mizrachi, MD7

1Emory University Winship Cancer Institute/ Department of Hematology and Medical Oncology, Atlanta, GA
2Kodikaz Therapeutic Solutions, LLC, new york, NY
3Winship Cancer Institute of Emory University, atlanta, GA
4Winship Cancer Institute of Emory University, Atlanta, GA
5Kodikaz Therapeutic Solutions, new york, NY
6Kodikaz Therapeutic Solutions, New York, NY
7Winship Cancer Institute/Department of Hematology and Medical Oncology, Emory University, atlanta, GA

Ricardo De Matos Simoes, PhD1,2*, Benjamin G Barwick, PhD3, Ryosuke Shirasaki, MD1,2,4*, Olga Dashevsky, PhD1,2*, Sara Gandolfi, MD, PhD1,2,5*, Huihui Tang, PhD1,2*, Brian Glassner, PhD1,2*, Richard W.J. Groen, PhD6, Daniel Auclair, PhD7, Aedin Culhane, PhD8*, Aviad Tsherniak, PhD2*, Francisca Vazquez, Phd2*, Jonathan D. Licht, MD9, Lawrence H. Boise, PhD10 and Constantine S. Mitsiades, MD, PhD1,2

1Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Broad Institute of MIT and Harvard, Cambridge, MA
3Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
4Dept. of Medical Oncology, Teikyo university hospital, Tokyo, TKY, Japan
5Translational Immunology Research program, University of Helsinki, Helsinki, MA, Finland
6University Medical Center Utrecht, Amsterdam, Netherlands
7Multiple Myeloma Research Foundation (MMRF), Norwalk, CT
8Dept. of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
9Department of Medicine, University of Florida, Gainesville, FL
10Emory University, Atlanta, GA

Mehmet K. Samur, PhD1,2, Anil Aktas-Samur, PhD3*, Romain Lannes, PhD4*, Jill Corre4*, Anjan Thakurta, PhD5*, Kenneth C. Anderson, MD6, Herve Avet-Loiseau7* and Nikhil C. Munshi, MD, PhD8

1Department of Data Science, Dana-Farber Cancer Institute, Harvard TH Chan School of Public Health, Boston, MA
2Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
4Unité de Génomique du Myélome, IUCT- Oncopole, Toulouse, France
5Translational Medicine, Bristol Myers Squibb, Summit, NJ
6Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
7Unite de Genomique du Myelome, IUC-Oncopole, Toulouse, France
8Dana-Farber Cancer Institute, Harvard Medical School, Boston

Ting DU, PhD1*, Yan Song, PhD1*, Arghya Ray, PhD1, Ruben D. Carrasco, MD, PhD2*, Sirano Dhe-Paganon, PhD1*, Dharminder Chauhan, PhD1* and Kenneth C. Anderson, MD3

1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
2Department of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA
3LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

Gemma Martinez-Rivas1*, Maria Ayala2*, Sebastien Bender, PhD3*, Michael Ehrmann4*, Murielle Roussel, MD1,5*, Arnaud Jaccard6,7*, Frank Bridoux, MD8* and Christophe Sirac7*

1CRIBL Lab, CNRS UMR7276 INSERM U1262, CNRS, INSERM, University of Limoges, Limoges, France
2UMR CNRS7276 INSERM1262, University of Limoges, LIMOGES, FRA
3CRIBL Lab, University Hospital Limoges, LIMOGES, FRA
4Center of Medical Biotechnology (ZMB), Faculty of Biology, University of Duisburg-Essen, Essen, Germany
5hematology, CHU de Limoges, Limoges, France
6CRIBL Lab, Centre Hospitalier Universitaire and Reference Center for AL Amyloidosis, Limoges, France
7CRIBL laboratory, CNRS UMR6101, Limoges, France
8CRIBL Laboratory, CHU Poitiers, CNRS UMR7276, Poitiers, FRA

Seth Welsh, PhD1*, Daniel Riggs, PhD1*, Erin Meermeier, PhD1*, Chang-Xin Shi, PhD1*, Victoria Garbitt1*, Meaghen E Sharik, BS1*, Megan Du1*, Kennedi Todd1*, Zachary Hammond1*, Sochilt Brown1*, Caleb K Stein, PhD1*, Paola Neri, MD, PhD2, Nizar J. Bahlis, MD2, Benjamin G Barwick, PhD3, Larry H. Boise, PhD4, W. Michael Kuehl, MD, PhD5*, Marta Chesi, PhD1 and P. Leif Bergsagel, MD1

1Division of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ
2Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
3Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
4Winship Cancer Institute, Emory University, Atlanta, GA
5National Cancer Institute, National Institutes of Health, Bethesda, MD

Rong Fan1*, Hatice Satilmis1*, Niels Vandewalle1*, Elke De Bruyne, PhD1*, Eline Menu, PhD1*, Andrew D Chantry, PhD, MD2*, Holly Evans, BSc2*, Marie Törngren3*, Helena Eriksson, PhD3*, Karine Breckpot, PhD4*, Ken Maes, PhD1*, Karin Vanderkerken, PhD1 and Kim De Veirman, PhD1*

1Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium
2Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, United Kingdom
3Active Biotech AB, Lund, Sweden
4Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium

Mary Sartor, BSc, PhD1*, Daniel Y Hu, PhD1*, Thomas X Lemarchand, DVM DESV-AP PhD DECVP2*, Luise Britz, BSc MSc PhD2*, Rosanne Dunn, PhD3* and David J Gottlieb, MD, MBBS, FRACP, FRCPA4*

1Centre for Cancer Research, Westmead Institute for Medical Research, Sydney, NSW, Australia
2TPL Path Labs GmbH, Freiburg, Germany
3Haemalogix Pty Ltd, Woolloomooloo, NSW, Australia
4Department of Haematology, Westmead Hospital, Sydney, Australia

Camila Guerrero1*, Noemi Puig, MD, PhD2, María Teresa Cedena, MD, PhD3*, Ibai Goicoechea, PhD1, Cristina Pérez Ruiz1*, Juan José Garcés1*, Cirino Botta, MD, PhD4, Maria Jose Calasanz, PhD, BSc1*, Norma C. Gutierrez2*, Maria Luisa Martin-Ramos3*, Albert Oriol5*, Rafael Rios, MD, PhD6*, Miguel Hernández7*, Rafael Martínez, M.D.8*, Joan Bargay9*, Felipe De Arriba, PhD10*, Luis Palomera, MD, PhD11*, Ana Pilar Gonzalez, PhD12*, Adrián Mosquera Orgueira13*, Marta Sonia Gonzalez, MD13*, Joaquín Martínez-López3*, Juan Jose Lahuerta, MD, PhD3*, Laura Rosinol14*, Joan Bladé Creixenti15, Maria-Victoria Mateos2, Jesus San-Miguel1 and Bruno Paiva, PhD1*

1Clinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369, Pamplona, Spain
2Hospital Universitario de Salamanca Hematología. Instituto de investigación biomédica de Salamanca (IBSAL), Salamanca, Spain
3Hospital Universitario 12 de Octubre, Madrid, Spain
4Hematology Unit, "Annunziata" Hospital of Cosenza, Cosenza, Italy
5Institut Català d'Oncologia L’Hospitalet, Barcelona, Spain
6Hospital Universitario Virgen de las Nieves, Instituto de Investigación Biosanitaria, Granada, Spain
7Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
8Hospital Universitario San Carlos, Madrid, Spain
9Hospital Universitario Son Llatzer, Institut d’ investigacio Illes Balears (IdISBa), Palma de Mallorca, Spain
10Hospital Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain
11Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
12Hospital Central de Asturias, Oviedo, Spain
13Complexo Hospitalario Universitario de Santiago de Compostela (CHUS), SERGAS, Santiago de Compostela, Spain
14Hematology Department, IDIBAPS, Hospital Clínic, Barcelona, Spain
15Amyloidosis and Multiple Myeloma Unit, Department of Hematology, IDIBAPS, Hospital Clínic, Barcelona, Spain, Barcelona, Spain

Raija Helena Silvennoinen, MD1,2, Komal Kumar Javarappa, PhD3, Sini Luoma, MD1*, Philipp Sergeev, MSc4*, Tiina J Öhman5*, Markku Varjosalo5*, Pekka Anttila, MD1*, Marjaana Säily, MD, PhD6*, Anu Partanen, MD, PhD2*, Marja Sankelo, MD, PhD7* and Caroline A. Heckman, PhD4

1Helsinki University Hospital, Comprehensive Cancer Center Hematology and University of Helsinki, Helsinki, Finland
2Department of Medicine, Kuopio University Hospital, Kuopio, Finland
3Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
4Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki, Finland
5CyTOF Unit, Viikki Campus, Helsinki, Finland
6Department of Internal Medicine, Hematology-Oncology Unit, Oulu University Hospital, Oulu, Finland
7Department of Hematology, Tampere University Hospital, Tampere, Finland

Osman Aksoy1*, Judith Lind, PhD1*, Vincent Sunder-Plassmann1*, Martin Percherstorfer, MD2*, Sonia Vallet, MD, PhD2* and Klaus Podar, MD, PhD1,2

1Karl Landsteiner University of Health Sciences, Krems, Austria
2Department of Internal Medicine II, University Hospital Krems, Krems, Austria

Tina Bagratuni, PhD1*, Foteini Aktypi, MSc2*, Maria Sakkou3,4,5*, Kleio Maria Verrou3*, Nefeli Mavrianou-Koutsoukou, BSc6*, Dimitrios Patseas7*, Christine Ivy Liacos, MSc2*, Stamatia Skourti8*, Alexandra Papadimou8*, Foteini Theodorakakou, MD2*, George Kollias3,4,5*, Petros Sfikakis, MD, PhD3,9*, Maria Gavriatopoulou, MD2*, Evangelos Terpos, MD, PhD2, Meletios A. Dimopoulos, MD2 and Efstathios Kastritis, MD2*

1Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Attiki, Greece
2Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3Center of New Biotechnologies & Precision Medicine, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4Department of Physiology, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
5Institute for Bioinnovation, Biomedical Sciences Research Center (BSRC) ‘Alexander Fleming’, Vari, Greece
6Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
7NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS, ATHENS, Greece
8Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
9Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece

Luca Heinmann1*, Helal Mohammed Mohammed Ahmed Noman, MBBS2, Klara Möllers1*, Subbaiah Chary Nimmagadda, PhD1*, Kaiyan Sun1*, Daria Frank, PhD1*, Hanna Korab3*, Lanying Wei4*, Anja Baumann3*, Alexandra Poos, PhD3*, Marc-Steffen Raab, MD5*, Georg Lenz, Prof., MD6 and Cyrus Khandanpour, PD, MD1

1Department of Medicine A, University Hospital Muenster, Muenster, Germany
2Department of Medicine A, University Hospital Muenster, Münster, Germany
3Clinical Cooperation Unit (CCU) Molecular Hematology/Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany
4Institute of Medical Informatics, University Hospital Muenster, Muenster, Germany., Muenster, Germany
5Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center (DKFZ) and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
6Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany

Emily Gallagher, MD PhD1*, Alessandro Lagana, PhD2,3,4,5*, Jasmine Huang, MD PhD6,7*, David T. Melnekoff, MS3,8,9,10*, Sundar Jagannath, MD3,9,11,12,13,14,15,16 and Samir Parekh, MD3,17,18,19,20

1Icahn School of Medicine At Mount Sinai, New York, NY
2Department of Oncological Sciences, Icahn School of Medicine At Mount Sinai, New York, NY
3Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
4Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York
5Institute for Next Generation Healthcare, Icahn School of Medicine at Mount Sinai, New York, NY
6Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
7Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
8Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
9Icahn School of Medicine at Mount Sinai, New York, NY
10Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, Brooklyn, NY
11Multiple Myeloma, Mount Sinai Cancer Institute, New York
12Mount Sinai Medical Center, New York, NY
13Department of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
14Department of Medicine, Hematology and Medical Oncology, Mount Sinai Medical Center, New York, NY
15Mount Sinai Hospital, New York, NY
16Multiple Myeloma Research Consortium, Norwalk, CT
17Hematology/Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
18Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY
19Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
20Mount Sinai School of Medicine, New York, NY

A. Keith Stewart, MBChB1, Zhihua Li, MSc2*, Olga Issakova, PhD3*, Nikolai Sepetov, PhD3* and Suzanne Trudel, MD2

1University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
3Nanosyn Inc., Santa Clara, CA

Tatsuya Konishi1*, Toshiki Ochi, MD, PhD1,2*, Masaki Maruta, MD, PhD1*, Kazushi Tanimoto, MD, PhD1*, Takashi Saitou, PhD3*, Takeshi Imamura, MD, PhD3*, Masaki Yasukawa, MD, PhD2,4* and Katsuto Takenaka, MD, PhD1

1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan
2Division of Immune Regulation, Proteo-Science Center, Ehime University, Ehime, Japan
3Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Ehime, Japan
4Ehime Prefectural University of Health Sciences, Ehime, Japan

Zachary J Walker, BS, MS1*, Rachel N Steinmetz, BSc2*, Denis J Ohlstrom, BS, MS3*, Lauren T Reiman, BSc1*, Taylor S Mills, BA1, Beau M Idler, BA4*, Brett M. Stevens, PhD1, Eric Pietras, PhD1 and Daniel W. Sherbenou, MD, PhD1

1Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO
2Department of Medicine, Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO
3School of Medicine, Emory University, Atlanta, GA
4Mayo Clinic Alix School of Medicine, Scottsdale, AZ

Marija K Simic1,2*, Sindhu T Mohanty1*, Ya Xiao1*, Tegan L Cheng3*, Feng Cong4*, Michael Daley4*, Peter I Croucher1,2* and Michelle M McDonald1,2*

1Healthy Ageing, Bone Biology Division, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
2St Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Kensington, NSW, Australia
3Centre for Children's Bone and Musculoskeletal Health, The Children's Hospital at Westmead, Westmead, NSW, Australia
4Novartis Institutes for Biomedical Research, Cambridge, MA

Jing Fu, PhD1, Shirong Li, PhD2*, Huihui Ma, MD, PhD3*, Jun Yang, MS2*, Lewis M Brown, PhD4*, Gabriel M. Pagnotti, PhD5*, Stephen J. Weiss, MD, PhD6*, Markus Y. Mapara, MD, PhD3 and Suzanne Lentzsch, MD, PhD2

1Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY
2Department of Medicine, Division of Hematology/Oncology, Columbia University Irving Medical Center, New York, NY
3Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY
4Quantitative Proteomics Center, Columbia University, New York, NY
5Department of Endocrine, Neoplasia and Hormonal Disorders, University of Texas - MD Anderson Cancer Center, Houston, TX
6Department of Internal Medicine, University of Michigan, Life Sciences Institute, Ann Arbor, MI

Maximilian Merz, MD1*, Lei Wei, PhD2*, Qiang Hu, PhD1*, Almuth Maria Anni Merz, MD2*, Jie Wang, PhD1*, Ahmed Belal, MD3*, Ronald Alberico, MD3*, Cherie Rondeau, NP1*, Kimberly Celotto, NP1*, AnneMarie W. Block, PhD2, Hemn Mohammadpour, PhD4, Paul K. Wallace, MS, PhD5, Joseph Dennis Tario, PhD2*, Jesse Luce3*, Sean Glenn, PhD3*, Prashant K Singh, PhD6*, David Barnidge, PhD7*, Song Liu, PhD8*, Philip L. McCarthy, MD9 and Jens Hillengass, MD, PhD2

1Roswell Park Comprehensive Cancer Center, Buffalo
2Roswell Park Comprehensive Cancer Center, Buffalo, NY
3Roswell Park Cancer Institute, Buffalo, NY
4Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY
5Flow & Image Cytometry, Roswell Park Comprehensive Cancer Center, Buffalo, NY
6Center for Personalized Medicine, Roswell Park Cancer Comprehensive Cancer Center, Buffalo, NY
7The Binding Site Inc., Rochester, MN
8Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, NY
9Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

Yuting Yan1*, Xiaoqi Qin2*, Jiahui Liu3*, Huishou Fan4*, Lanting Liu5*, Zhen Yu5*, Shuhui Deng, MD3*, Wei Liu3*, Dehui Zou6*, Lugui Qiu3 and Gang An7*

1Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science, Tianjin, China
3State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4National Clinical Research Center for Blood Diseases, State Key Laboratory of Experimental Hematology, Blood Diseases Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
6Department of Lymphoma & Myeloma, Institute of Hematology & Blood Diseases Hospital, State Key Laboratory of Experimental Hematology, Chinese Academy of Medical Sciences & Peking Union of Medical College, Tianjin, China
7Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, China

Simone A Minnie, PhD1*, Nicole S Nemychenkov1*, Shuichiro Takahashi, MD, PhD1*, Christine R Schmidt1*, Samuel RW Legg1*, Kathleen S Ensbey1* and Geoffrey R Hill, MD1,2

1Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
2Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA

Zuzana Chyra1,2,3*, Srikanth Talluri, PhD4,5*, Rao Prabhala, PhD4,5, Mehmet K. Samur, PhD6,7*, Anil Aktas-Samur, PhD8,9*, Yan Xu, MD10,11*, Aaron B. Beeler, PhD12*, Roman Hajek, MD, PhD13,14,15, Mariateresa Fulciniti, PhD10, Masood A. Shammas, PhD5,16* and Nikhil C. Munshi, MD, PhD17,18,19

1The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, Boston, MA
2Department of Hemato-Oncology,, University Hospital Ostrava, Ostrava, Czech Republic
3Department of Internal Studies, University of Ostrava, Ostrava, Czech Republic
4Dana-Farber Cancer Institute, Boston, MA
5VA Boston Healthcare System, Boston, MA
6Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
7The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
8Department of Data Science, Dana Farber Cancer Institute, Boston, MA
9Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA
10Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
11Institute of Hematology & Blood Diseases Hospital, Chinese Academic Medical Science & Peking Union Medical College, Tianjin, China
12Department of Chemistry and Center for Molecular Discovery, Boston University, Boston
13Czech Myeloma Group, Brno, Czech Republic
14Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic
15Faculty of Medicine, Department of Clinical Studies, University of Ostrava, Ostrava, Czech Republic
16The Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston
17Dana-Farber Cancer Institute, Harvard Medical School, Boston
18Boston VA Healthcare System, West Roxbury, MA
19Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

Aditi Sharma, PhD1*, Abhinav Achreja, PhD2,3*, Remya Nair, PhD1*, Pulkit Gupta1*, Claudia L Edgar, BS1*, Olamide Animasahun, BS3,4*, Anjali Mittal, BS3,4*, Bhakti Dwivedi, PhD5*, Manoj Bhasin, PhD6, Vikas A Gupta, MD, PhD1*, Benjamin G Barwick, PhD1, Shannon M Matulis, PhD1*, Sagar Lonial, MD, FACP1, Lawrence H. Boise, PhD1, David L Jaye, MD7, Arun P Wiita, MD, PhD8, Ajay K. Nooka9, Deepak Nagrath, MS, PhD2,3,4* and Mala Shanmugam, PhD10

1Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
2Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI
3Biointerfaces Institute, University of Michigan, Ann Arbor, MI
4Department of Chemical Engineering, University of Michigan, Ann Arbor, MI
5Department of Biostatistics and Bioinformatics Shared Resource, Winship Cancer Institute, Emory University, Atlanta, GA
6Department of Pediatrics, Emory University School of Medicine, Atlanta, GA
7Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Dunwoody, GA
8Department of Laboratory Medicine, UCSF, San Francisco, CA
9Department of Hematology and Medical Oncology, Winship Cancer Insitute, Emory University School of Medicine, Atlanta, GA
10Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA

Olga Dashevsky, PhD1,2*, Ricardo De Matos Simoes, PhD1,2*, Benjamin G Barwick, PhD3, Sara Gandolfi, MD, PhD1,2,4*, Ryosuke Shirasaki, MD2,5*, Michal Sheffer, PhD1,2*, Aedin Culhane, PhD6*, Richard WJ Groen7*, Aviad Tsherniak, PhD1*, Francisca Vazquez, Phd1*, Jonathan D. Licht, MD8, Lawrence H. Boise, PhD9 and Constantine S. Mitsiades, MD, PhD1,2

1Broad Institute of MIT and Harvard, Cambridge, MA
2Dept. of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
3Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
4Translational Immunology Research program, University of Helsinki, Helsinki, MA, Finland
5Dept. of Medical Oncology, Teikyo university hospital, Tokyo, TKY, Japan
6Dept. of Biostatistics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
7VU University Medical Center, Amsterdam, NLD
8Department of Medicine, University of Florida, Gainesville, FL
9Emory University, Atlanta, GA

Chad C Bjorklund, PhD1*, Michael Amatangelo, PhD2*, Hsiling Chiu, MS2*, Jian Kang3*, Tiziana Civardi4*, Jessica Katz, MD PhD3*, Paulo Maciag, MD PhD3*, Patrick Hagner, PhD3*, Michael Pourdehnad, MD PhD5*, Nizar J. Bahlis, MD6, Paul G. Richardson, MD7,8 and Anjan Thakurta, PhD9*

1Translational Medicine-Hematology, Bristol Myers-Squibb, SUMMIT, NJ
2Bristol Myers Squibb, Summit, NJ
3Bristol Myers Squibb, Princeton, NJ
4Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
5Early Clinical Development, Hematology/Oncology and Cell Therapy, Bristol Myers Squibb, Princeton, NJ
6Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
7Dana-farber/Boston Children's Cancer and Blood Disorders Ctr, Boston, MA
8Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
9Translational Development and Diagnostics, Bristol Myers Squibb, Summit, NJ

Cristina Panaroni, PhD1, Keertik Fulzele, PhD2*, Tomoaki Mori, MD, PhD1*, Rie Nakamoto-Matsubara, MD, PhD1*, Allison Maebius, MSc1* and Noopur S. Raje, MD1

1Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, Boston, MA
2Constellation Pharma, Cambridge, MA

Sayak Chakravarti, MSc, BSc1*, Suman Mazumder, PhD2,3*, Harish Kumar, PhD2, Neeraj Sharma, PhD4*, Ujjal Kumar Mukherjee, PhD5*, Shaji K Kumar, MD6, Linda B Baughn, PhD7, Brian G. Van Ness, PhD8 and Amit Kumar Mitra, PhD, MSc, BSc2,3

1Harrison School of Pharmacy, Auburn, AUBURN, AL
2Harrison School of Pharmacy, Auburn University, Auburn, AL
3Center for Pharmacogenomics and Integrated Omics Initiative, Auburn University, Auburn, AL
4Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
5University of Illinois - Urbana Champaign, Champaign, IL
6Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
7Division of Laboratory Genetics, Mayo Clinic, Rochester, MN
8Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN

*signifies non-member of ASH